Aldagen has dropped plans for its proposed initial public offering for the second time, The Wall Street Journal reports. The drug developer was seeking to raise about $80.5 million from the offering, which was launched in October 2009, adds Business Journal.

Aldagen called off the IPO plans due to unfavorable market conditions. The Durham, North Carolina-based company had previously withdrawn a proposed listing in 2008.

Click here for the story from The Wall Street Journal.

Click here for the additional coverage from Business Journal.